Drugs & Targets FDA approves FoundationOne CDx as a Companion Diagnostic for Piqray in new indication December 06, 2019Vol.45 No.45
Drugs & Targets FDA grants Priority Review to Merck’s Supplemental Biologics License Application for Keytruda in NMIBC indication December 06, 2019Vol.45 No.45
Drugs & Targets FDA accepts NDA for pemigatinib in previously treated, locally advanced or metastatic cholangiocarcinoma with FGFR2 fusions or rearrangements December 06, 2019Vol.45 No.45
Drugs & Targets China approves Keytruda for first-line treatment in metastatic squamous NSCLC+chemo indication December 06, 2019Vol.45 No.45
Drugs & Targets Lynparza approved in China as a first-line maintenance therapy in BRCA-mutated advanced ovarian cancer indication December 06, 2019Vol.45 No.45
Clinical Roundup Study finds wide county-level variation in rates of surgery for early-stage lung cancer December 06, 2019Vol.45 No.45
Clinical Roundup Tecentriq + Avastin combination demonstrates improvement in OS, PFS in HCC December 06, 2019Vol.45 No.45
Clinical Roundup Alunbrig demonstrates reduced risk of death, disease progression in ALK+ NSCLC December 06, 2019Vol.45 No.45
Clinical Roundup Experimental targeted therapy may be better for repeat kidney cancer patients than FDA-approved counterpart, study finds December 06, 2019Vol.45 No.45
Clinical Roundup Duke researchers develop technique to visually depict how cancer cells grow and spread in colon tissue December 06, 2019Vol.45 No.45
